Sociedad Americana de Hirudoterapia

Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment

Research article published in Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2018)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Meta-analysisEnsayos clínicosBariteau et al. · Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2018

Abstract

BACKGROUND: This systematic review addresses the controversy over the decision to anticoagulate patients with subsegmental pulmonary embolism (SSPE). METHODS: We searched Ovid MEDLINE, PubMed, Embase, the Cochrane Library, Scopus, Web of Science, ClinicalTrials.gov, Google Scholar, and bibliographies in March 2017. Two authors reviewed and retained papers with symptomatic patients who underwent computerized tomographic pulmonary angiography and had sufficient information to determine SSPE; decision to treat (or not) with systemic anticoagulation; and outcomes of bleeding, venous thromboembolism (VTE) recurrence, and death. Papers were assessed for selection and publication bias and heterogeneity, with Eggers and the inconsistency indexes (I2 ). RESULTS: From 1,512 papers screened, we included 14 studies comprising 15,563 patients for full-length review and analysis. Pooled data demonstrated I2  = 99% with an Eggers p < 0.001, suggesting significant publication bias. The pooled prevalence of SSPE was 4.6% (95% confidence interval [CI] = 1.8%-8.5%). The frequency of bleeding in SSPE patients treated with anticoagulation (n = 589) was 8.1% (95% CI = 2.8%-15.8%), with no available bleeding data in untreated patients (n = 126). The frequency of VTE recurrence within 90 days was 5.3% (95% CI = 1.6%-10.9%) for treated versus 3.9% (95% CI = 4.8%-13.4%) for untreated, while the frequency of death was 2.1% (95% CI = 3.4%-5.2%) for treated versus 3.0% (95% CI = 2.8%-8.6%) for untreated. CONCLUSION: This systematic review highlights the lack of any clinical trial to make a clear inference about harm or benefit of anticoagulation for SSPE. Comparison of pooled data from uncontrolled outcome studies shows no increase in VTE recurrence or death rates for patients who were not anticoagulated. These data suggest clinical equipoise for decision to anticoagulate or not anticoagulate patients with SSPE. However, this inference is limited by small numbers, imprecision, and the lack of a controlled clinical trial.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMeta-AnalysisResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tSystematic Review
Indexed MeSH termsAnticoagulantsHemorrhageHumansPrevalencePulmonary EmbolismRecurrenceThrombolytic TherapyVenous Thromboembolism

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Esta revisión sistemática y metaanálisis agrupó 14 estudios (15,563 pacientes) para analizar si la embolia pulmonar subsegmentaria (SSPE) debe ser anticoagulada, y no encontró un aumento claro en la recurrencia de VTE o muerte entre los pacientes que no recibieron tratamiento, concluyendo que existe un equilibrio clínico y que no hay ningún ensayo controlado que determine el daño frente al beneficio. Para ASH, el valor es contextual más que directo: ilustra cuán escasa y cuestionada puede ser la base de evidencia de la anticoagulación incluso para una indicación convencional, que es la misma arena de balance entre trombosis y sangrado a la que finalmente se refiere la historia del anticoagulante salival de la sanguijuela (hirudin y moléculas relacionadas del secretoma). Advertencia honesta: este artículo trata sobre fármacos anticoagulantes sistémicos para SSPE, no sobre hirudoterapia ni ningún agente derivado de sanguijuelas, y los propios autores subrayan que los datos están limitados por números pequeños, una heterogeneidad severa, sesgo de publicación y la ausencia de cualquier RCT.

Citación

Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment.

Bariteau et al. · Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2018

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.